Bassetti Matteo, Carnelutti Alessia, Righi Elda
Infectious Diseases Division, Santa Maria Misericordia Hospital, Udine, Italy.
Curr Opin Infect Dis. 2017 Apr;30(2):150-157. doi: 10.1097/QCO.0000000000000353.
Methicillin-resistant Staphylococcus aureus (MRSA) has become a major public health issue worldwide over the last years. MRSA is frequently implicated in the development of skin and soft tissue infections, leading to significant increases in morbidity, mortality and overall healthcare costs.
In order to face the threat of MRSA, major changes in clinical management of skin and soft tissue infections are required. The identification of populations at risk for the acquisition of infections due to MRSA, together with the improvement of the diagnostic techniques, is paramount. Moreover, a number of new antimicrobials with activity against MRSA have been recently developed and approved for the treatment of skin and soft tissue infections, however, the use of the new drugs in the wide clinical practice remains limited.
We reviewed the current epidemiology of MRSA in skin and soft tissue infections, with particular focus on implications for clinical management. The potential role of new antibiotic options against MRSA infections is also discussed.
在过去几年中，耐甲氧西林金黄色葡萄球菌（MRSA）已成为全球主要的公共卫生问题。MRSA常与皮肤和软组织感染的发生有关，导致发病率、死亡率和整体医疗费用显著增加。
为应对MRSA的威胁，皮肤和软组织感染的临床管理需要重大变革。识别有感染MRSA风险的人群以及改进诊断技术至关重要。此外，最近已研发并批准了多种对MRSA有活性的新型抗菌药物用于治疗皮肤和软组织感染，然而，这些新药在广泛临床实践中的应用仍然有限。
我们综述了MRSA在皮肤和软组织感染中的当前流行病学情况，特别关注其对临床管理的影响。还讨论了新型抗生素对MRSA感染的潜在作用。
